23 Jul, 2026
According to Straits Research, the global hospital acquired infection (HAI) control market size was valued at $21.36 billion in 2025 and is projected to grow from $22.70 billion in 2026 to $37.90 billion by 2034, registering a CAGR of 6.62% during the forecast period 2026–2034.
A drug infusion system is a medical device used to administer fluids, drugs, and therapeutic substances directly into a patient's bloodstream in a controlled and regulated manner. These systems are widely employed in various healthcare settings, such as hospitals, clinics, ambulatory care, and home healthcare. Drug infusion systems are critical in delivering medications and therapies such as chemotherapy, pain management, insulin administration, and antibiotic administration, among others.
The drug infusion system market share is expected to increase during the forecast period due to factors such as increasing prevalence of chronic diseases such as cardiovascular disease, strokes, cancer, type 2 diabetes, and so on, growing geriatric population, technological advancements, rising healthcare expenditure, portability and ease of use, and visual monitoring features. Nonetheless, the high cost of drug infusion systems, a scarcity of experienced professionals, and stringent government regulations are projected to impede market expansion throughout the projection period.
North America had a market share of 50.77% in 2025, governed by stringent regulatory frameworks and institutional reporting requirements that compel hospitals to invest in advanced prevention and surveillance technologies. High prevalence of HAIs has driven healthcare providers to adopt comprehensive sterilization, disinfection and monitoring protocols backed by robust reimbursement incentives. Advanced healthcare infrastructure and higher per-capita healthcare spending allow hospitals to integrate data-driven HAI surveillance systems and generate outcome data to reduce infection rates, creating sustained demand for control solutions.
The Asia Pacific market is anticipated to register the fastest CAGR of 8.62% during the forecast period. The market is shaped by rapid expansion of healthcare infrastructure, increasing hospital admissions and rising awareness of infection control practices across developing and developed nations. Growing incidence of HAIs, especially in densely populated countries, prompts adoption of basic IPC measures alongside scalable sterilization and hygiene products tailored to varying facility capabilities. Governments are updating national IPC guidelines to improve surveillance and reporting, which in turn stimulates investment in products and training.
The contents of the report are as follows:
sales@straitsresearch.com